Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 100 of 5804
-
New hope for Hard-to-Treat lymphoma: targeted drug combo shows promise in phase 3 trial
Disease control CompletedThis study is a multicenter, open-label study of polatuzumab vedotin administered by intravenous (IV) infusion in combination with rituximab, gemcitabine and oxaliplatin (R-GemOx) in participants with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The study compris…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Stem cell heart patch could be lifeline for failing hearts
Disease control Recruiting nowThe BioVAT-HF trial will test the hypothesis that cardiomyocyte implantation via engineered heart muscle (EHM), the proposed investigational medicinal product (IMP; designated "Biological Ventricular Assist Tissue" or BioVAT), results in sustainable remuscularization and biologic…
Phase: PHASE1, PHASE2 • Sponsor: University Medical Center Goettingen • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Could a stem cell infusion free kidney transplant patients from lifelong drugs?
Disease control Recruiting nowThis study will determine whether a preparatory regimen including total lymphoid irradiation (TLI), total body irradiation (TBI), anti-thymocyte globulin (ATG) and infusion of the donor hematopoietic stem cells when given along with recipient regulatory T cells (Tregs) will allow…
Phase: PHASE1 • Sponsor: Stanford University • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New targeted combo shows promise in slowing advanced breast cancer
Disease control OngoingThis study will evaluate the efficacy, safety, and pharmacokinetics of inavolisib in combination with palbociclib and fulvestrant compared with placebo plus palbociclib and fulvestrant in participants with PIK3CA-mutant, hormone receptor (HR)-positive, HER2-negative locally advan…
Phase: PHASE2, PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Monthly shot could free kids with hemophilia from frequent infusions
Disease control OngoingPrimary Objective: \- To confirm appropriate dose levels of fitusiran when administered to male pediatric participants (ages 1 to \<12 years of age) with severe hemophilia A or B Secondary Objectives: * To characterize the safety and tolerability * To determine fitusiran plasm…
Phase: PHASE2, PHASE3 • Sponsor: Genzyme, a Sanofi Company • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Magic mushroom compound shows promise for depression in large trial
Symptom relief CompletedOne hundred participants, ages 21 to 65, who meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for major depressive disorder (MDD) will be stratified by study site and randomized with a 1-to-1 allocation under double-blind conditions to receive a single …
Phase: PHASE2 • Sponsor: Usona Institute • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
Blood test may decide who needs chemo after colon cancer surgery
Disease control Recruiting nowThe objective of CIRCULATE trial is to improve care of patients after colon tumor surgery, based on an innovative marker: circulating tumor DNA.
Phase: PHASE3 • Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Heart attack prevention revolution? CT scan may beat standard risk scores
Prevention OngoingIt is hypothesised that, in individuals being considered for cardiovascular preventative therapy, computed tomography coronary angiography guided management will reduce the future risk of coronary heart disease death or non-fatal myocardial infarction compared to management guide…
Phase: NA • Sponsor: University of Edinburgh • Aim: Prevention
Last updated Jun 27, 2026 08:12 UTC
-
New pill takes on chemo for rare lung cancer
Disease control OngoingThe purpose of this study is to compare effectiveness of TAK-788 as first-line treatment with that of platinum-based chemotherapy in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors has epidermal growth factor receptor (EGFR) exon 2…
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Promising drug combo shows hope for slowing rare gut tumors
Disease control OngoingThe aim of NETTER-2 was to determine if Lutathera in combination with long-acting octreotide prolongs progression free survival (PFS) in gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients with high proliferation rate tumors (G2 and G3), when given as a first line trea…
Phase: PHASE3 • Sponsor: Advanced Accelerator Applications • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New urine test could spot deadly pancreatic cancer sooner
Diagnosis OngoingUrine and blood samples are being collected from patients with and without diseases of the pancreas. These samples will be tested with the aim of developing an accurate way of diagnosing diseases of the pancreas using the results.
Sponsor: Queen Mary University of London • Aim: Diagnosis
Last updated Jun 27, 2026 12:04 UTC
-
Can a targeted drug plus donor immune cells fight back against relapsed leukemia?
⭐️ CURE ⭐️ CompletedThis study includes patients with relapsed acute leukemia who have previously been treated with standard treatment that is still present and there is no curative treatment option available. Researchers are studying whether the drug Gemtuzumab Ozogamicin, followed by an infusion o…
Phase: PHASE1, PHASE2 • Sponsor: Brown University • Aim: ⭐️ CURE ⭐️
Last updated Jul 25, 2026 00:00 UTC
-
New drug cocktail aims to stop liver cancer recurrence after surgery
Disease control CompletedThis study will evaluate the efficacy and safety of adjuvant therapy with atezolizumab plus bevacizumab compared with active surveillance in participants with completely resected or ablated hepatocellular carcinoma (HCC) who are at high risk for disease recurrence.
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo aims to keep bladder cancer from coming back
Disease control OngoingThe purpose of this study is to learn about the safety and effects of the study medicine (sasanlimab) in people with non-muscle invasive bladder cancer. This study is seeking participants whose bladder cancer is still in early stages, has not spread outside of the bladder, has be…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Could adding capecitabine boost chemo success in Triple-Negative breast cancer?
Disease control OngoingPrimary aim: To compare the effect on pathologic complete response (pCR) rate of adding capecitabine to carboplatin based preoperative chemotherapy in early ER-negative and HER2-negative breast cancer. Pembrolizumab is allowed in both arms after approval for TNBC 2022.
Phase: PHASE3 • Sponsor: Lund University Hospital • Aim: Disease control
Last updated Jun 26, 2026 15:52 UTC
-
Could a stem cell transplant tame Hard-to-Control MS?
Disease control Recruiting nowThis is a multi-center prospective rater-masked (blinded) randomized controlled trial of 156 participants, comparing the treatment strategy of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) to the treatment strategy of Best Available Therapy (BAT) for treatment-resist…
Phase: PHASE3 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New immunotherapy combo aims to fight advanced liver cancer
Disease control OngoingThis is a multi-center, double-blind, randomized, phase III study to investigate the efficacy and safety of Nofazinlimab (CS1003) in combination with lenvatinib and placebo in combination with lenvatinib in the treatment of subjects with no prior systemic treatment and with unres…
Phase: PHASE3 • Sponsor: CStone Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New drug aims to cut heart attacks in High-Risk patients
Disease control OngoingThis is a pivotal phase 3 study designed to support an indication for the reduction of cardiovascular risk in patients with established CVD and elevated Lp(a)
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Engineered immune cells take aim at childhood brain cancers
Disease control Recruiting nowThis is a Phase 1 study of central nervous system (CNS) locoregional adoptive therapy with autologous CD4+ and CD8+ T cells lentivirally transduced to express a B7H3-specific chimeric antigen receptor (CAR) and EGFRt. CAR T cells are delivered via an indwelling catheter into the …
Phase: PHASE1 • Sponsor: Seattle Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Immunotherapy before Chemo-Radiation shows promise for Hard-to-Treat cancers
Disease control Recruiting nowThe purpose of this study is to find out whether the study drug, TSR-042, followed by standard chemoradiotherapy (the chemotherapy drug capecitabine + radiation therapy) and standard surgery is an effective treatment for advanced dMMR solid tumors. The study will also look at the…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC